Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 NIAID, BioCryst Exercise Development Option | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

NIAID, BioCryst Exercise Development Option

Aims to advance drug for Marburg virus through Phase I

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option under its agreement with BioCryst Pharmaceuticals for the conduct of an IND program for the development of BCX4430 as a treatment for Marburg virus disease. BioCryst will receive an additional $2.5 million, which follows an initial award of $5.0 million in September 2013. The total funding could reach $22.0 million during the next five years.
 
The goal of the contract is to file INDs for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease and to advance the program through Phase I trials.
 
“With these additional funds, BioCryst will rapidly initiate IND-enabling studies of intramuscular BCX4430,” said Dr. William P. Sheridan, chief medical officer at BioCryst. “This is an important next step in moving the development program forward to an IND submission, leading to an initial safety trial in healthy human volunteers.”
 
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics